drugset / Trial / NCT07048886

Rocklatan Adds Pressure Reduction After MIGS (Minimally Invasive Glaucoma Surgery)

NCT07048886

Phase 4 Not yet recruiting 68 enrolled Center for Sight Las Vegas
RandomizedParallel-groupDouble-blindTreatment

Summary

The primary objective of this study is to determine if the addition of Rocklatan post-Hydrus will provide additional intraocular pressure lowering.

Timeline

Start
2025-07-15
Primary completion
2026-12-31
Completion
2026-12-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator Rocklatan Other / unclassified 0.005 %
Comparator Rocklatan Other / unclassified 0.02 %

Indications